PMV Pharmaceuticals, Inc
PMVPPMV Pharmaceuticals, Inc. is a biotechnology company focused on developing targeted therapies that modulate p53, a tumor suppressor protein involved in preventing cancer. The company is dedicated to advancing precision medicines for cancer patients with p53 mutations, leveraging its proprietary p53 reactivation platform.
Company News
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a f...
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreement for the acquisition of NextTrip Holdings, Inc. Bio-Path Holdings, Inc. (NASDAQ: BPTH) shares climbed 102% to $0.7961 after gaining more than 6% on Thursday. Shift Technologies, Inc. (NASDAQ: SFT) ga...
Halvorsen's 13F portfolio value decreased from $34.49B to $24.74B this quarter. The top 3 positions are T-Mobile US, Amazon.com, and General Electric, together, at ~16% of the portfolio.
Related Companies
